Tenaya Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Tenaya Therapeutics, Inc. (TNYA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 143.17 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 177.14M shares, a 40.49% increase year-over-year.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 126.09M shares, a 907.12% increase year-over-year.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 12.52M shares, a 37.06% increase year-over-year.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 9.13M shares, a 87.09% increase year-over-year.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 172.89M shares, a 1503.82% increase from fiscal 2024.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.78M shares, a 14.30% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.43M shares, a 66.34% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.67M shares, a 102.43% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 143.17M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 177.14M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 172.89M shares 10-K · filed 2026-03-11 | |||
| 2025-09-30 | 126.10M shares 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 126.87M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 126.09M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 10.78M shares 10-K · filed 2026-03-11 | |||
| 2024-09-30 | 11.32M shares 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 12.07M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 12.52M shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 9.43M shares 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 9.32M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 9.48M shares 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | 9.13M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 5.67M shares 10-K · filed 2024-03-18 | |||
| 2022-09-30 | 5.27M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 5.25M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 4.88M shares 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 2.80M shares 10-K · filed 2023-03-08 | |||
| 2021-09-30 | 2.57M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 28.26M shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 27.93M shares 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 25.79M shares 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 18.85M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 18.90M shares 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |